BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus Reports Third Quarter 2026 Financial Results

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsEarnings

Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch Appointed Neera Clase as Chief Commercial Officer Management

Related news

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-10-29 20:30 EST

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

LCTXLineage Cell Therapeutics2026-11-05 13:00 EST

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

SGHTSight Sciences2026-11-04 21:05 EST

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

IRIXIRIDEX2026-11-03 21:05 EST

Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026

OCULOcular Therapeutix2026-11-02 12:00 EST

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

LENZLenz Therapeutics Inc2026-10-28 20:30 EST

LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession

OCGNOcugen2026-10-22 11:00 EST

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-11-05 21:30 EST

Tarsus to Participate in Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2026-11-03 21:05 EST

Tarsus Reports Third Quarter 2026 Financial Results

TARSTarsus Pharmaceuticals2026-10-29 20:30 EST

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

TARSTarsus Pharmaceuticals2026-10-28 12:30 EST

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

TARSTarsus Pharmaceuticals2026-09-29 12:30 EST

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

Stock data

Close
67.52 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States